Displaying results 1 - 10 / 24
results / page
What publication information is included in the service?
Publication name
Authors
Publication channel
Year
Publications information icon

Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab

Peer-reviewed
DOI
10.1016/j.critrevonc.2017.01.001
Wahid, Mohd; Akhter, Naseem; Jawed, Arshad; Dar, Sajad A.; Mandal, Raju K.; Lohani, Mohtashim; Arees...
Critical Reviews in Oncology / Hematology2017Publications information icon

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma

Peer-reviewed
Open access
DOI
10.1016/j.ejca.2018.11.031
Auvray, Marie; Auclin, Edouard; Barthelemy, Philippe; Bono, Petri; Kellokumpu-Lehtinen, Pirkko; Gros...
European journal of cancer2019Publications information icon

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Peer-reviewed
Open access
DOI
10.1056/nejmoa1712126
Motzer, R;Tannir, N;McDermott, D;Arén, Frontera O;Melichar, B;Choueiri, T;Plimack, E;Barthélémy, P;P...
new england journal medicine2018Publications information icon

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma:CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

Peer-reviewed
Open access
DOI
10.1200/JCO.19.00538
Sharma, Padmanee; Siefker-Radtke, Arlene; de Braud, Filippo; Basso, Umberto; Calvo, Emiliano; Bono, ...
Journal of clinical oncology2019Publications information icon

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

Peer-reviewed
Auvray M; Auclin E; Barthelemy P; et al; Kellokumpu-Lehtinen P
European Journal of Cancer2019Publications information icon

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032):a multicentre, open-label, phase 1/2 trial

Peer-reviewed
Open access
DOI
10.1016/S1470-2045(16)30098-5
Antonia, Scott J.; Lopez-Martin, Jose A.; Bendell, Johanna; Ott, Patrick A.; Taylor, Matthew; Eder, ...
The Lancet Oncology2016Publications information icon

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Peer-reviewed
Motzer RJ; Rini BI; Mcdermont DF; et al; Kellokumpu-Lehtinen PL
Lancet Oncology2019Publications information icon

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial

Peer-reviewed
Open access
DOI
10.1001/jamaoncol.2018.4514
Ascierto, Paolo A.; Long, Georgina V.; Robert, Caroline; Brady, Benjamin; Dutriaux, Caroline; Di Gia...
JAMA oncology2019Publications information icon

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

Peer-reviewed
Open access
DOI
10.1200/JCO.20.00995
Robert, Caroline; Long, Georgina V.; Brady, Benjamin; Dutriaux, Caroline; Di Giacomo, Anna Maria; Mo...
Journal of clinical oncology2020Publications information icon

Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma

Peer-reviewed
Open access
DOI
10.1158/2767-9764.CRC-22-0514
Lee, Moon Hee; Theodoropoulos, Jason; Huuhtanen, Jani; Bhattacharya, Dipabarna; Järvinen, Petrus; To...
Cancer research communications2023

Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab

Peer-reviewed
DOI
10.1016/j.critrevonc.2017.01.001
2017

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma

Peer-reviewed
Open access
DOI
10.1016/j.ejca.2018.11.031
2019

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Peer-reviewed
Open access
DOI
10.1056/nejmoa1712126
2018

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma:CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

Peer-reviewed
Open access
DOI
10.1200/JCO.19.00538
2019

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

Peer-reviewed
2019

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032):a multicentre, open-label, phase 1/2 trial

Peer-reviewed
Open access
DOI
10.1016/S1470-2045(16)30098-5
2016

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Peer-reviewed
2019

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial

Peer-reviewed
Open access
DOI
10.1001/jamaoncol.2018.4514
2019

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

Peer-reviewed
Open access
DOI
10.1200/JCO.20.00995
2020

Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma

Peer-reviewed
Open access
DOI
10.1158/2767-9764.CRC-22-0514
2023